Study of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
An Open-label, Phase 2 Study to Assess the Safety and Efficacy of EQ101 in Adult Subjects With Moderate to Severe Alopecia Areata
Sponsor: Equillium
A PHASE2 clinical study on Alopecia and Alopecia Areata, this trial is completed. The trial is conducted by Equillium and has accumulated 8 data snapshots since 2022. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
May 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — May 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
Status: Active Not Recruiting → Completed
-
Jan 2024 — Jul 2024 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Aug 2023 — Jan 2024 [monthly]
Recruiting PHASE2
▶ Show 3 earlier versions
-
Apr 2023 — Aug 2023 [monthly]
Recruiting PHASE2
-
Mar 2023 — Apr 2023 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Nov 2022 — Mar 2023 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Equillium
- Equillium AUS Pty Ltd
For direct contact, visit the study record on ClinicalTrials.gov .